ASTM E2474-14 PDF

Full title and description

ASTM E2474-14 — Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology. This practice describes a science- and risk-based approach to designing pharmaceutical manufacturing processes that use Process Analytical Technology (PAT) to develop process understanding, enable control strategies, and support post‑development optimization for both drug substance and drug product operations.

Abstract

This practice provides guidance for practical implementation and experimental development of process understanding using PAT. It covers activities and outcomes of process design (including design of new processes and improvement/redesign of existing ones) and emphasizes risk assessment, data‑driven experimental design, multivariate tools, analyzers, and process control to achieve a desired state and fit‑for‑purpose manufacturing. The guidance is applicable to drug substance and drug product processes; for drug products it integrates formulation and process development considerations.

General information

• Status: Withdrawn (withdrawal recorded July 6, 2020).
• Publication date: April 1, 2014 (designation E2474‑14; previous edition E2474‑06).
• Publisher: ASTM International.
• ICS / categories: 11.120.01 — Pharmaceutics in general.
• Edition / version: E2474‑14 (2014 edition).
• Number of pages: 3 pages.

Scope

This practice covers pharmaceutical process design as an integral component of process development and of post‑development process optimization. It addresses both the activities used to design processes and the resulting designed processes. The principles apply to new process development and to improvement or redesign of existing processes, for drug substances and finished drug products, and focus on practical, experimental approaches to attain process understanding supported by PAT. Safety, health, and regulatory applicability are the responsibility of the user.

Key topics and requirements

• Definition and objectives of process design in the pharmaceutical context (activities and outcomes).
• Integration of Process Analytical Technology (PAT) into process development and manufacturing.
• Risk assessment and mitigation as part of process design and control strategy development.
• Data collection planning and formal experimental design (DoE) to build process understanding.
• Use of multivariate data analysis and statistical tools for process characterization.
• Selection and application of process analyzers and real‑time measurement technologies.
• Intrinsic performance assessment and establishing process fitness‑for‑purpose.
• Manufacturing strategy considerations, including continuous vs. batch approaches and design space concepts.
• Process control approaches, including PAT‑enabled control systems and continuous improvement expectations.

Typical use and users

Intended users include pharmaceutical process development scientists, manufacturing engineers, PAT specialists, quality assurance and quality control professionals, regulatory affairs staff, and consultants working on process design, technology transfer, and process improvement. The practice was used to inform internal process design decisions, design space and control strategy development, and to guide PAT implementation and experimental programs.

Related standards

Closely related guidance and standards include other ASTM and industry documents addressing process understanding, PAT implementation, verification of PAT‑enabled control systems, and equipment/system specification and verification. International and regulatory guidance on quality by design (QbD), PAT, and pharmaceutical quality systems (for example ICH Q8/Q9/Q10 and regional regulatory PAT/QbD guidances) are complementary to the topics covered by this practice.

Keywords

Process Analytical Technology; PAT; pharmaceutical process design; process understanding; design space; quality risk management; multivariate analysis; design of experiments (DoE); process control; analyzers; manufacturing strategy; continuous improvement.

FAQ

Q: What is this standard?

A: ASTM E2474‑14 is a short ASTM practice titled "Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology" that provided guidance on applying PAT and data‑driven methods to pharmaceutical process design and optimization.

Q: What does it cover?

A: It covered practical implementation and experimental development of process understanding using PAT, including risk assessment, experimental design and data collection, multivariate tools, process analyzers, intrinsic performance assessment, manufacturing strategy, and process control for drug substance and drug product processes.

Q: Who typically uses it?

A: Users included process development scientists, PAT engineers, manufacturing and QA/QC personnel, regulatory affairs specialists, technology transfer teams, and consultants involved in pharmaceutical manufacturing and process optimization.

Q: Is it current or superseded?

A: This practice was published April 1, 2014 (E2474‑14) and was withdrawn in July 2020. It was withdrawn without direct replacement due to limited industry use; users should consult current ASTM guides and relevant regulatory/ICH guidance for up‑to‑date expectations and any successor guidance.

Q: Is it part of a series?

A: It was developed under ASTM Committee E55 (Manufacture of Pharmaceutical and Biopharmaceutical Products) and is conceptually linked to other ASTM and industry documents on process understanding, PAT, and equipment/system specification and verification (for example related ASTM guides and documents addressing PAT verification, multivariate analysis, and process/system specification).

Q: What are the key keywords?

A: Key keywords are Process Analytical Technology (PAT), process design, process understanding, design space, multivariate analysis, design of experiments (DoE), process control, quality risk management, and manufacturing strategy.